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Abstract Carcinogens induce carcinogen-specific genetic in-
stability (defects in DNA repair). According to the ‘direct-
selection’ model, defects in DNA repair per se provide an
immediate growth advantage. According to the ‘associated-
selection’ model, carcinogens merely select for cells with adaptive
mutations. Like any mutations, adaptive mutations occur
predominantly in genetically unstable cells. The ‘associated-
selection’ model predicts that carcinogen-driven selection mini-
mizes cytotoxic but maximizes mutagenic effects of carcinogens.
A purely mutagenic (neither cytotoxic, nor cytostatic) environ-
ment will favor effective DNA repair, whereas any growth-
limiting conditions (telomerase deficiency, anticancer drugs) will
select for genetically unstable cells. Genetic instability is a
postmark of selective pressure rather than a hallmark of cancer
per se. Once selected, genetic instability facilitates the develop-
ment of resistance to any other growth-limiting conditions. As an
example, a putative link between prior exposure to carcinogens
and the ability to develop a telomerase-independent growth is
discussed. ß 2001 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
DNA repair exists to repair DNA. Therefore, one expects
that cells that have survived exposure to DNA-damaging car-
cinogens will e¡ectively repair DNA. It may seem logical that
inhibition of DNA repair will increase the cytotoxicity of
alkylating agents, which damage DNA. This paradigm is a
basis for combining of alkylating drugs (which damage
DNA) with novobiocin (which inhibits DNA repair) for the
treatment of cancer [1].
On the other hand, a recent publication by Bardelli et al.
describes that mutagenic carcinogens, including alkylating
agents, select for cells with carcinogen-speci¢c genomic insta-
bility. Furthermore, cells with carcinogen-speci¢c genomic in-
stability survive exposure to carcinogens [2]. Although these
results are somehow contraintuitive, they have been theoret-
ically predicted [3]. In a highly mutagenic environment, it
might be too ‘costly’ for a cell to repair DNA [4]. According
to this view, it is DNA repair that is harmful for cells exposed
to a mutagen. Futile cycles of DNA repair is a growth dis-
advantage in a mutagenic environment [4]. Vice versa defec-
tive DNA repair (genomic instability) provides an immediate
growth advantage.
However, even if genetic instability has no immediate
growth advantage, these phenomena (namely: (i) mutagenic
carcinogens select for carcinogen-speci¢c genomic instability,
and (ii) carcinogen-speci¢c genomic instability allows cells to
survive exposure to carcinogens) can be predicted.
Furthermore, the alternative model explains and predicts a
broad range of unrelated events from telomerase-independent
growth and cell immortalization to induction of genetic insta-
bility in normal cells following treatment of leukemia. But
more on this later.
1.1. Carcinogen-speci¢c genetic instability
Di¡erent forms of DNA damage require di¡erent sensing
and repair enzymes. Thus, there are separate types of genetic
instability. For example, chromosomal instability (CIN) is
manifested by chromosomal rearrangements leading to aneu-
ploidy. Numerous agents including bulky-adduct-forming
(BAF) agents cause chromosomal rearrangements. BAF-in-
duced DNA damage is repaired by nucleotide excision. BAF
mutagens select for cells with defects in nucleotide excision
repair, that in turn precludes the repair of DNA damage
caused by BAF [2].
Another type of genomic instability, microsatellite instabil-
ity (MIN), is characterized by de¢ciency in nucleotide mis-
match repair. Alkylating carcinogens cause G/T mismatches
and select cells with a de¢ciency in nucleotide mismatch repair
[2]. In brief, carcinogens favor the breakdown of the speci¢c
repair of DNA damage which is in£icted by this carcinogen
[3,4].
1.2. Genetic instability
A high mutation rate due to genetic instability is a hallmark
of cancer. Genetic instability appears early in carcinogenesis
[3,5]. However, elevated mutation rate, per se, cannot explain
the rise and expansion of cells with elevated mutation rate [3].
How is genetic instability selected? There are essentially two
models that may describe this process. Ironically, they are
used interchangeably, as one model, because they share a
common element: selection for growth advantage. Genetic
instability may provide an immediate growth advantage (di-
rect-selection). Alternatively, genetic instability provides no
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immediate growth advantage but it is selected in association
with growth-promoting mutations.
1.3. Direct-selection model: mutagen-driven selection
In a highly mutagenic environment, DNA repair may limit
cell growth [4]. Under highly mutagenic environment, it may
be too costly to repair mutations. By employing only one
factor (mutagenesis), this concept explains a carcinogen-driv-
en selection. I will refer to this concept as to as ‘direct-selec-
tion (mutagen-driven)’ model (Fig. 1A). Although the appeal
of this model is that one single factor (mutagenic environ-
ment) both creates a mutation repertoire and selects for ge-
nomic instability, the problem is that it must be reconciled
with the fact that DNA repair exists, generally speaking, in
order to repair DNA.
1.4. Two elements of selection
Selection depends on two essential elements, i.e. availability
of genetic variation and selection barrier [5]. Selection pres-
sure is the major driving force in tumorigenesis [6]. Selection
barrier eliminates sensitive cells, selecting for adaptive muta-
tions. Adaptive mutations, predominantly arise in cells with a
high mutation rate. In other words, genetic instability pro-
vides a repertoire of mutants from which cytotoxic pressure
selects favorable variants.
In normal conditions, when cells are adapted to their envi-
ronment, there is no selection pressure. Given that most mu-
tations are deleterious, mutations are repaired and a low mu-
tation rate is sustained (Fig. 1B). A purely mutagenic
environment favors e¡ective DNA repair. In theory, a muta-
gen that is not cytotoxic will not select for genomic instability
(Fig. 1B). Under cytotoxic conditions only, a cell should
adapt to the environment in order to survive. Then a muta-
tion repertoire is needed. Genetically stable cells cannot over-
come a selective barrier [5]. And an exposure to carcinogen is
a selective barrier.
1.5. Dissociation of mutagenic and cytotoxic e¡ects
Cytotoxic and mutagenic e¡ects of carcinogens are not nec-
essarily hardwired. In theory, two agents (mutagen and cyto-
toxin) can replace one carcinogen (Fig. 1C). There are several
lines of evidence that mutagenic (DNA-damaging) and cyto-
toxic e¡ects can be separated. First, many carcinogens (e.g.
TPA) are cytotoxic/cytostatic but are not mutagenic [7]. Sec-
ond, a mutagenic agent by itself is not necessarily cytotoxic.
Thus, somatic cells might tolerate the production of large
numbers of mutations [7]. Genetically unstable cells (e.g. can-
cer cells) are highly viable. The cytotoxicity of DNA-damag-
ing (mutagenic) agents in part depends on the activation of
apoptotic pathways [8]. In turn, apoptosis can be inhibited
without any e¡ects on DNA strand breaks and their repair.
1.6. Association-selection model: cytotoxicity-driven selection
Cytotoxicity-driven selection is the basis for the ‘associated-
selection’ model (Fig. 1C). Why does a carcinogen select for
genomic instability? Technically speaking, it does not. A car-
cinogen selects for mutations that confer resistance to its cy-
totoxicity, but these mutations happen to occur in genetically
unstable cells (Fig. 1C). In other words, ‘genetic instability is
observed in the ¢nal tumor because the instability mutations
propels progression and is carried along as a passenger with
the clonally selected alterations’ [5].
1.7. Direct- versus associated-selection models
According to the associated-selection model, ‘when a cell
inactivates an instability gene, there is no immediate growth
advantage to that cell’ [5]. In contrast, the direct-selection
model demands that ‘if a mutated instability gene is selected
Fig. 1. Two models: selection for genomic instability. A: The direct-selection (mutation-driven) model. DNA repair, rather than DNA damage,
causes cytotoxicity. Repair-de¢cient cells are selected in highly mutagenic environment. B: According to the associated-selection model, pure
mutagens (non-cytotoxic agents) do not select for genetic instability. C: Associated-selection (cytotoxicity-driven) model. In genetically stable
cells, DNA is repaired, and there will be no pool of mutations to select for resistance. The population of genetically stable cells will be elimi-
nated. In repair-de¢cient cells, there will be a pool of mutations from which to select for resistance to cytotoxic pressure. The cytotoxicity-driv-
en selection results in both resistance and genomic instability
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during tumor progression it must be related to the growth
advantage of this genetic alteration’ [3].
The direct-selection model has emerged to solve ‘the para-
dox that a DNA-damaging and repair-demanding environ-
ment potentiates the growth advantage of repair de¢ciency’
[3]. According to the associated-selection model, there is no
paradox in the ¢rst place. It is a growth-limiting (not ‘DNA-
damaging and repair-demanding’) environment which favors
a repair de¢ciency.
2. Predictions of the associated-selection model
2.1. Carcinogen-speci¢c genetic instability according to the
associated-selection model
As discussed, a mutation repertoire is required to select for
a carcinogen-resistant phenotype. Under cytotoxic conditions,
carcinogen-speci¢c genetic instability merely re£ects the need
in a mutation repertoire. To acquire a mutation, both DNA
damage and failure to repair this damage are needed. Obvi-
ously, DNA damage and repair de¢ciency should match each
other. Because carcinogens caused carcinogen-speci¢c dam-
age, it must be complemented by carcinogen-speci¢c repair
defects. BAF agents, which induce chromosome breaks, select
for the inability to repair these breaks (CIN) [2]. Alkylating
agents, which cause nucleotide mismatch, select for a de¢-
ciency in nucleotide mismatch repair (MIN) [2].
A cytotoxic mutagen selects for a speci¢c kind of repair
de¢ciency which maximizes the number of mutations.
Although the goal is not selection for genomic instability
but selection for resistance, it could be only achieved by max-
imizing a mutation rate. Carcinogen-driven selection mini-
mizes cytotoxic e¡ects and maximizes mutagenic e¡ects of
carcinogens (Fig. 1C).
2.2. Cytotoxic/cytostatic conditions favor genetic instability
The associated-selection model predicts that cytotoxic
agents, lacking any mutagenic activities, must select for genet-
ic instability. Indeed, hypoxia, low pH, and nutrient depriva-
tion induce genetic instability [9]. As another example, a
monomer of plastics (which is not mutagenic) induces cellular
transformation and aneuploidy (genetic instability) [10]. A
plausible reinterpretation of these phenomena is that hypoxia,
deprivation, plastics, etc. select for rather than induce genetic
instability. Hypoxia selects for hypoxia resistance causing tu-
mor progression [11]. Genetic instability is an universal phe-
nomenon in cancer because it is ‘selected’ even by non-muta-
genic carcinogens. Due to endogenous sources of mutations
[12], carcinogens are not necessarily mutagenic. Furthermore,
genetic instability is not restricted to cancer. For example,
genetic instability arises in normal T cells from patients who
had received chemotherapy for B-lineage acute lymphocytic
leukemia [13]. Genomic instability also occurs in ulcerative
colitis [14]. Genetic instability is a postmark of selective pres-
sure rather than a hallmark of cancer.
2.3. Defects in mismatch repair promote telomerase-
independent proliferation
The title of a recent paper in Nature indicates that defects in
mismatch repair promote telomerase-independent prolifera-
tion in yeast [15]. On the other hand, telomere dysfunctions
increase a mutation rate in yeast [16]. This relationship be-
tween telomere dysfunction and genetic instability is a remi-
niscent of the relationship between carcinogens and genetic
instability. Carcinogens promote genetic instability and genet-
ic instability promotes cells’ survival. Yet, the link between
carcinogen-promoted and telomerase-independent growth is
not obvious. UnlessT we simply consider a telomere shorten-
ing as a growth-limiting condition.
2.4. Telomere shortening as a growth-limiting condition
Telomeres (the ends of chromosomes) are essential for chro-
mosomes maintenance. Telomeres shorten with each cell cycle
because DNA polymerases do not replicate the very end of
telomeres. This shortening limits the number of cell divisions.
Telomeres can be maintained (in germline and cancer cells) by
telomerase, a reverse transcriptase that ‘synthesize’ telomeres.
But telomeres also can be maintained by an alternative mech-
anism: by a homologous recombination [17]. Like mutations
caused by alkylating agents, a homologous recombination is
prevented by mismatch repair machinery.
Telomerase-negative mutant yeast cells undergo telomere
shortening over many cell divisions. Survivors maintain their
telomeres. Telomere shortening is a growth-limiting condition
that selects for longer (recombinant) telomeres. Telomeres re-
combination occurs in mismatch repair-de¢cient cells. It is not
surprisingly that mismatch repair-de¢cient cells displayed
growth advantage [15]. Technically, defective repair does not
Fig. 2. Genetic instability and telomerase-independent proliferation.
As a particular case of the associated-selection model (Fig. 1C),
telomerase de¢ciency and mismatch repair de¢ciency correspond
to cytotoxicity and mutagen, respectively.
Fig. 3. Carcinogen-selected genetic instability permits immortaliza-
tion.
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promote proliferation. Defective repair increases the fre-
quency of recombinations, leading to longer telomeres. It is
longer telomeres, not genetic instability, which is selected. But
longer telomeres occur in cells with mismatch repair de¢ciency
(Fig. 2). Thus, telomerase de¢ciency selects for mismatch re-
pair de¢ciency.
2.5. Carcinogen exposure and telomere dysfunction:
barriers or promoters
As recently emphasized, it might seem paradoxical that the
cytotoxicity caused by telomere erosion promotes cancer ini-
tiation [18]. According to the cytotoxicity-driven (associated-
selection) model, this is exactly what one should expect. A
selective barrier such as telomere dysfunction can either pro-
mote or inhibit immortalization and carcinogenesis. Develop-
ment of cancer in telomerase-de¢cient mice required inactiva-
tion of p53 [19]. Inactivation of p53 leads to genetic instability
[20]. Inactivation of p53 converts telomere based crisis from
the barrier to tumor development into one that enhances can-
cer initiation [18]. In theory, a prior exposure to a carcinogen
can substitute for p53 inactivation. By selecting for carcino-
gen-tolerance, carcinogens indirectly select for genetic insta-
bility (Fig. 3). In turn, genetic instability may permit telomer-
ase-independent growth (or immortalization) (Fig. 3).
Telomere erosions limit growth and cause senescence of cells
that were not exposed to carcinogens and retain pro¢cient
mismatch repair (Fig. 3). A selective barrier is a hurdle for
cells with a low mutation rate but it is a tumor promoter for
cells with a high mutation rate.
2.6. Conclusion: combining alternative paradigms
Genetic instability is a well-recognized hallmark of cancer
[3,5,7]. The concept of cancer as a mutator phenotype is based
on the rarity of mutations in normal cells and the high fre-
quency of mutations in malignant cells [21]. The question is
how is genetic instability induced. The concept, which I refer
to as the associated-selection model, has been described pre-
viously [5], but it was not clearly distinguished from ‘coexist-
ing’ direct-selection model. In a broader sense, two models
which describe selection of genetic instability (direct- and as-
sociated-selection) stand between two extreme views. First
view is that selection is not necessary for a rise of genetic
instability which is, accordingly, a simple accumulation of
mutations in genes that repair DNA. Accordingly, carcino-
genic environment is essentially mutagenic. For example, raise
of genetic instability in chronic ulcerative colitis, a premalig-
nant condition, can be explained by the production of muta-
genic radicals. ‘The amount of damage may exceed the ca-
pacity of the DNA repair machinery, resulting in mutations
including in genes that e¡ect genetic instability’ [22]. This
example however also supports the thesis that cytotoxic
(non-mutagenic) environment in ulcerative colitis selects for
genetic instability. By dissociating mutagenic and cytotoxic
e¡ects of carcinogens, this review envisions the associated-se-
lection model as cytotoxicity-driven selection. The model pre-
dicts that a purely mutagenic environment favors DNA re-
pair, whereas cytotoxic environment favors genetic
instability. This thesis is best supported by examples of selec-
tion for genetic instability by non-mutagenic carcinogens,
hypoxia, and anticancer drugs. Genetic instability is a post-
mark of cytotoxic selective pressure. Although it is a hallmark
of many cancers, it is not necessarily restricted to cancer.
On the other extremity, it has been argued that increased
mutagenesis is not required to produce the multiple mutations
observed in cancer. A raised mutation rate may make evolu-
tion (or tumorigenesis) faster, but is not necessary for evolu-
tion (or tumorigenesis) to occur [6].
Regardless of whether genetic instability is necessary or
unnecessary for tumorigenesis, the associated-selection model
predicts an increase in genetic instability during tumor pro-
gression. As mentioned a high mutation rate may make tu-
morigenesis faster [6], and this di¡erence may be crucial for
the development of overt cancer in our limited life span. Be-
cause the cytotoxicity-driven selection for genomic instability
is £exibly associated with carcinogenesis, the time of rise of
genetic instability is also £exible: it may precede cancer
[14,22], it may appear early in carcinogenesis [23^25], or it
may be selected after overt cancerous alterations occur
[6,26,27].
References
[1] Kennedy, M.J., Armstrong, D.K., Huelskamp, A.M., Ohly, K.,
Clarke, B.V., Colvin, O.M., Grochow, L.B., Chen, T.L. and Da-
vidson, N.E. (1995) J. Clin. Oncol. 13, 1136^1143.
[2] Bardelli, A., Cahill, D.P., Lederer, G., Speicher, M.R., Kinzler,
K.W., Vogelstein, B. and Lengauer, C. (2001) Proc. Natl. Acad.
Sci. USA 98, 5770^5775.
[3] Breivik, J. and Gaudernack, G. (1999) Semin. Cancer Biol. 9,
245^254.
[4] Breivik, J. (2001) Proc. Natl. Acad. Sci USA 98, 5379^5381.
[5] Cahill, D.P., Kinzler, K.W., Vogelstein, B. and Lengauer, C.
(1999) Trends Cell Biol. 9, M57^60.
[6] Tomlinson, I. and Bodmer, W. (1999) Nat. Med. 5, 11^12.
[7] Loeb, L.A. (2001) Cancer Res. 61, 3230^3239.
[8] Kaufmann, S.H. and Gores, G.J. (2000) Bioessays 22, 1007^
1017.
[9] Reynolds, T.Y., Rockwell, S. and Glazer, P.M. (1996) Cancer
Res. 56, 5754^5757.
[10] Tsutsui, T., Tamura, Y., Suzuki, A., Hirose, Y., Kobayashi, M.,
Nishimura, H., Metzler, M. and Barrett, J.C. (2000) Int. J. Can-
cer 86, 151^154.
[11] Blagosklonny, M.V. (2001) Int. J. Oncol. 19, 257^262.
[12] Ames, B.N. (2001) Mutat. Res. 475, 7^20.
[13] Finette, B.A., Homans, A.C. and Albertini, R.J. (2000) Science
288, 514^517.
[14] Willenbucher, R.F., Aust, D.E., Chang, C.G., Zelman, S.J., Fer-
rell, L.D., Moore, D.H. and Waldman, F.M. (1999) Am. J. Path-
ol. 154, 1825^1830.
[15] Rizki, A. and Lundblad, V. (2001) Nature 411, 713^716.
[16] Hackett, J.A., Feldser, D.M. and Greider, C.W. (2001) Cell 106,
275^286.
[17] Dunham, M.A., Neumann, A.A., Fasching, C.L. and Reddel,
R.R. (2000) Nat. Genet. 26, 447^450.
[18] Chang, S., Khoo, C. and DePinho, R.A. (2001) Semin. Cancer
Biol. 11, 227^239.
[19] Chin, L., Artandi, S.E., Shen, Q., Tam, A., Lee, S.L., Gottlieb,
G.J., Greider, C.W. and DePinho, R.A. (1999) Cell 97, 527^
538.
[20] Funk, J.O., Samuel, T. and Weber, H.O. (2001), in: Blagos-
klonny, M.V. (Ed.), Cell Cycle Checkpoints and Cancer, pp.
65^78, Landes Bioscience, Austin, TX.
[21] Loeb, L.A., Spinggate, C.F. and Battula, N. (1974) Cancer Res.
34, 2311^2321.
[22] Loeb, K.R. and Loeb, L.A. (1999) Am. J. Pathol. 154, 1621^
1626.
[23] Fearon, E.R. and Vogelstein, B. (1990) Cell 61, 759^767.
[24] Kinzler, K.W. and Vogelstein, B. (1996) Cell 87, 159^170.
[25] Lengauer, C., Kinzler, K.W. and Vogelstein, B. (1998) Nature
396, 643^649.
[26] Homfray, T.F., Cottrell, S.E., Ilyas, M., Rowan, A., Talbot, I.C.,
Bodmer, W.F. and Tomlinson, I.P. (1998) Hum. Mutat. 11, 114^
120.
[27] Bodmer, W.F. (1999) Ann. Acad. Med. Singap. 28, 323^329.
FEBS 25291 5-10-01
M.V. Blagosklonny/FEBS Letters 506 (2001) 169^172172
